Hematology - European Medical Journal

This site is intended for healthcare professionals

Continue

Hematology

Filter
10 Mins
13 Dec 2018

Editor’s Pick: Newest Approaches in Immunotherapy for Non-Hodgkin’s Lymphoma

Immunotherapy has revolutionised the treatment of haematologic malignancies. Patients with relapsed/refractory non-Hodgkin’s lymphoma have poor response…
8 Mins
4 Sep 2018

Editor’s Pick: Chimeric Antigen Receptor-Engineered T Cell Therapy in Acute Myeloid Leukaemia

Acute myeloid leukaemia (AML) is a disease with a very poor outcome and remains an area of significant unmet need, necessitating novel therapeutic…
12 Mins
4 Sep 2018

Epstein–Barr Virus: A Biological Overview and Clinicopathological Changes of Two Epstein–Barr Virus-Related Lymphoproliferative Disorders in a World Health Organization (WHO) 2017 Report

Epstein–Barr virus (EBV) is one of the most important viral causes for the development of tumours. The global geographical epidemiology of EBV shows…
10 Mins
4 Sep 2018

A Game of Clones: The Complex Interplay of Aplastic Anaemia, Myelodysplastic Syndrome, and Paroxysmal Nocturnal Haemoglobinuria

Although idiopathic aplastic anaemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal haemoglobinuria (PNH) are all associated with…
6 Mins
2 Aug 2018

Planning Your Next Move in Philadelphia Chromosome Positive Leukaemias

The meeting was arranged as a series of conversations between experts, following a question and answer format with two speakers in each presentation…
9 Mins
2 Aug 2018

Editor's Pick: Allogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors

The introduction of tyrosine kinase inhibitors (TKI) has dramatically improved the prognosis of chronic myeloid leukaemia (CML) patients and, therefore…
10 Mins
2 Aug 2018

Therapeutic Options in Myelodysplastic Syndromes: Established and Emerging Therapies

Although hypomethylating agents (HMA) have revolutionised the treatment of myelodysplastic syndromes (MDS), a significant proportion of patients either…
11 Mins
2 Aug 2018

Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy

The humanised anti-CD20 antibody (Ab) rituximab (RTX) has significantly improved the prognosis of B cell non-Hodgkin’s lymphomas (BNHL). However, major…
We’ve noticed you’re accessing
from North/South America.